Skip to Content

ADREVIEW 74 MBQ/ML SOLUTION FOR INJECTION

Active substance(s): METAIODOBENZYLGUANIDINE (I-123)

View full screen / Print PDF » Download PDF ⇩
Transcript
DEU

GBR
GE HealthcareGE Healthcare

AdreViewTM
74 MBq/ml solution for injection
[123 I] iobenguane
CY 13

1

1

7

3

6

D_GGBRTP.02

2

6

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AdreView 74 MBq/ml solution for injection
(called AdreView in this leaflet)
[123I]iobenguane
Read all of this leaflet carefully before you are given AdreView.
 Keep this leaflet. You may need to read it again.
 If you have any further questions, ask your doctor.
If you get any side effects, talk to your doctor or nurse. This includes
any possible side effects not listed in this leaflet. See section 4.
In this leaflet:
1. What AdreView is and what it is used for
2. What you need to know before you are given AdreView
3. How AdreView is given
4. Possible side effects
5. How to store AdreView
6. Further information
1. What AdreView is and what it is used for
This medicine is for diagnostic use only. It is used only to help identify
illness.
AdreView is a ‘radiopharmaceutical’ medicine. It is given before a scan
and helps a special camera see inside a part of your body.
 It contains an active ingredient called ‘iobenguane’.
 Once injected it can be seen from outside your body by a special
camera used in the scan.
 The scan can help your doctor see certain types of tumour in the
adrenal or thyroid glands, and to see how well a tumour is
responding to treatment.
 Some other people are given this medicine before a scan to see
how well the heart is working.
Your doctor or nurse will explain which part of your body will be
scanned.
2. What you need to know before you are given AdreView
You should not be given AdreView:
 If you are allergic to the active ingredient or any other ingredients
of this product (listed in Section 6).
Warnings and precautions
Children: Premature babies or newborn babies (neonates) must not
be given AdreView. (See “Important information about some of the
ingredients of AdreView”).

Talk to your doctor or nurse before you are given AdreView if you are
on a low sodium diet.
Other medicines and AdreView
Please tell your doctor or nurse if you are taking or have recently
taken any other medicines, including medicines obtained without a
prescription. This includes herbal medicines. This is because some
medicines can affect the way AdreView works.
Before your scan tell your doctor or nurse if you are taking any of the
types of medicine below. This is because they may affect the results of
your scan:
 Calcium-channel blockers such as diltiazem, nifedipine or
verapamil.
 Antidepressants such as amitryptiline or imipramine.
 ‘Sympathomimetic agents’ (used as decongestants in cough or
cold remedies) such as phenylephrine, ephedrine or
phenylpropanolamine.
 Reserpine (used to treat mental problems or high blood pressure).
 Labetalol (used to treat high blood pressure).
 Phenothiazine (used to treat mental problems).
 Cocaine.
If you are not sure if any of the above apply to you, talk to your doctor
or nurse before having AdreView.
Pregnancy and breast-feeding
You must tell your doctor if you are pregnant or think you might be
pregnant. Your doctor will only use AdreView if it is considered that
the benefit outweighs the risk.
Do not breast-feed if you are given AdreView. This is because small
amounts of ‘radioactivity’ may pass into the mother’s milk. If you are
breast-feeding, your doctor may wait until you have finished breastfeeding before using AdreView. If it is not possible to wait your doctor
will ask you to:
 stop breast-feeding for 3 days, and
 use formula feed for your child, and
 express (remove) breast milk and throw away the milk.
Your doctor will let you know when you can start breast-feeding
again.
Driving and using machines
Ask your doctor if you can drive or use machines after you have been
given AdreView.
Important information about some of the ingredients of AdreView
 AdreView contains benzyl alcohol. Benzyl alcohol may cause toxic
reactions and allergic reactions in infants and children up to 3
years old.

Important information about AdreView
When AdreView is used you are exposed to radioactivity.
 Your doctor will always consider the possible risks and benefits
before you are given the medicine.
Ask your doctor if you have any questions.
3. How AdreView is given
AdreView will be given to you by a specially trained and qualified
person.
 AdreView will always be used in a hospital or clinic.
 Your doctor will tell you to take another medicine 24 to 48 hours
before you are given AdreView. You will continue to take this
medicine for at least 3 days. This medicine is to stop radioactivity
building up in your thyroid gland.
 They will tell you anything you need to know for its safe use.
Your doctor will decide on the dose that is best for you.
The usual dose is:
 A single injection given over several minutes.
You will usually have your scan the day after the injection and it may
be repeated.
4. Possible side effects
Like all medicines, AdreView can cause side effects, although not
everybody gets them.
Allergic reactions
If you have an allergic reaction when you are in hospital or a clinic
having the scan, tell the doctor or nurse straight away. The signs may
include:
 skin rash or itching or flushing
 swelling of the face
 difficulty breathing
In more serious cases reactions may include:
 passing out (unconsciousness), feeling dizzy or lightheaded
 nausea (feeling sick)
 cold chills
If any of the side effects above happen after you leave the hospital or
clinic, you should go or be taken straight to the casualty department
of your nearest hospital.
The frequency of allergic reactions cannot be estimated from the
available data
Other side effects include
If AdreView is injected too quickly you may experience the following:
 fast or irregular heart beat
 difficulty breathing
 feeling warmer than usual

 stomach cramps
 high blood pressure. Signs of this may be headache and changes in
your eyesight (visual disturbance).
If any of the side effects gets serious, or if you notice any side effects
not listed in this leaflet, please tell your doctor or nurse.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes
any possible side effects not listed in this leaflet.
You can also report side effects directly via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard.
5. How to store AdreView
AdreView is kept out of the reach and sight of children.
The product label includes the correct storage conditions and the
expiry date for the batch. Hospital staff will ensure that the product is
stored and disposed of correctly and not used after the expiry date
stated on the label.
6. Further information
What AdreView contains
 The active ingredient is [123I]iobenguane. Each ml of AdreView
contains 74 MBq (Megabecquerel – the unit in which radioactivity is
measured) of [123I]iobenguane at a fixed time.
 The other ingredients are benzyl alcohol,
3-iodobenzylguanidine, sodium dihydrogen phosphate dihydrate,
disodium hydrogen phosphate dihydrate and water for injections.
What AdreView looks like and contents of the pack
AdreView is supplied as a single glass vial containing a solution for
injection.
Marketing Authorisation Holder
GE Healthcare Limited
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
United Kingdom
Manufacturer
GE Healthcare B.V.
Den Dolech 2
5612 AZ Eindhoven
The Netherlands
This leaflet was last approved in 09/2015.
Marketing Authorisation
UK: PL 00221/0140

PACKAGE LEAFLET: INFORMATION FOR HEALTHCARE PROFESSIONAL
1.

NAME OF THE MEDICINAL PRODUCT
AdreView 74 MBq/ml solution for injection

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION
[123I]iobenguane, 37 to 740 MBq, 74 MBq/ml at calibration date and hour.
At calibration time, the radionuclidic purity is at least 99.95% iodine-123 and the main radionuclidic
impurities being iodine-125 and tellurium-121 occur for less than 0.05%. The radiochemical purity is at
least 97% [123I]iobenguane and the main radiochemical impurity is iodine-123 which is present for less
than 3% during the shelf-life (see section 6.3).
The specific activity is greater than 0.15 and less than 1.5 TBq/mmol (0.46-4.6 GBq/mg iobenguane
sulphate).
Iodine-123 is a cyclotron produced radionuclide with a physical half-life of 13.2 h, which decays to
tellurium-123 by electron capture.
Most important gamma radiation emitted:
Energy level
Abundance (%)
159 keV
83.6
This medicinal product contains:
 Benzyl alcohol: 10.4 mg/ml
 Sodium: 4.23 mg/ml. This needs to be taken into consideration for patients on a controlled sodium
diet.
For a full list of excipients, see section 6.1.
The contents of the vial may be used for one or more administrations until time of expiry.

3.

PHARMACEUTICAL FORM
Solution for injection
Clear, colourless solution.

4.

CLINICAL PARTICULARS

4.1. Therapeutic indications
This medicinal product is for diagnostic use only.
Diagnostic scintigraphic localisation of tumours originating in tissue that embryologically stems from
the neural crest. These are pheochromocytomas, paragangliomas, chemodectomas and
ganglioneuromas.
Detection, staging and follow-up on therapy of neuroblastomas.
Evaluation of the uptake of iobenguane. The sensitivity to diagnostic visualisation is different for the
listed pathological entities.
Pheochromocytomas and neuroblastomas are sensitive in approx. 90% of patients, carcinoids in 70%
and MCT in only 35%.
Functional studies of the adrenal medulla (hyperplasia) and the myocardium (sympathetic innervation).
4.2. Posology and method of administration
Posology
[123I]iobenguane is administered according to the following dosage scheme:
Paediatric population
- Children under 6 months (must not be given to premature babies or neonates – see section 4.4):
4 MBq per kg body weight (max. 40 MBq)
- Children between 6 months and 2 years: 4 MBq per kg body weight (min. 40 MBq).
- Children over 2 years: a fraction of the adult dosage should be chosen, dependent on body weight.
The recommended dosages are as follows:
weight activity
weight activity
weight activity
3 kg 20 MBq
15 kg 76 MBq
35 kg 140 MBq
4 kg 28 MBq
20 kg 92 MBq
40 kg 152 MBq
6 kg 38 MBq
25 kg 110 MBq
45 kg 162 MBq
8 kg 46 MBq
30 kg 124 MBq
50 kg 176 MBq
10 kg 54 MBq
Adults
 Adults: the recommended dosage is 80-200 MBq, higher activities may be justifiable.
 No special dosage scheme is required for the elderly patient.
Method of administration
[123I]iobenguane is administered by slow intravenous injection or infusion. If desired the
administration volume can be increased by dilution.
The instructions for preparation of radiopharmaceuticals are given in section 12.
4.3. Contra-indications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Must not be given to premature babies or neonates.

4.4. Special warnings and precautions for use
 Paediatric population: This medicinal product contains benzyl alcohol (approx. 10 mg/ml). Benzyl
alcohol may cause toxic reactions and anaphylactoid reactions in infants and children up to 3
years old.
 Potential for hypersensitivity or anaphylactic reactions. If hypersensitivity or anaphylactic reactions
occur, the administration of the medicinal product must be discontinued immediately and
intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the
necessary medicinal products and equipment such as endotracheal tube and ventilator must be
immediately available.
 Drugs known or expected to reduce the [123I]iobenguane uptake should be stopped before
treatment (usually 4 biological half-lives).
 Thyroid blockade is started 24-48 hours before the [123I]iobenguane is administered and continued
for at least 3 days. Blockade by potassium perchlorate is achieved by administration of approx.
400 mg/day. Blockade by potassium iodide, potassium iodate or Lugol solution must be performed
with an equivalent of 100 mg of iodine/day.
 The dose is slowly administered intravenously over several minutes.
 Whole body anterior and posterior scintigraphic images and/or relevant spot images and/or SPECT
images are obtained 24 hours after the [123I]iobenguane administration. These views are eventually
repeated at 48 hours.
 The uptake of iobenguane in the chromaffin granules might, in theory, cause rapid noradrenalin
secretion which can induce a hypertensive crisis. This necessitates constant monitoring of the
patient during administration. [123I]iobenguane must be administered slowly (take at least one
minute for the administration of a patient dose).
4.5. Interaction with other medicinal products and other forms of interaction
The following drugs are known or may be expected to prolong or to reduce the uptake of iobenguane
in neural crest tumours.
 Nifedipine (a Ca-channel blocker) is reported to prolong retention of iobenguane.
 Decreased uptake was observed under therapeutic regimens involving the administration of
antihypertensives that deplete norepinephrine stores or reuptake (reserpine, labetalol), calciumchannel blockers (diltiazem, nifedipine, verapamil), tricyclic antidepressives that inhibit
norepinephrine transporter function (amitryptiline, imipramine and derivatives), sympathomimetic
agents (present in nasal decongestants, such as phenylephrine, ephedrine, pseudoephedrine or
phenylpropanolamine), cocaine, and phenothiazine. These drugs should be stopped before
administration of [123I]iobenguane (usually for four biological half-lives to allow complete washout).
4.6. Fertility, pregnancy and lactation
Pregnancy

When it is necessary to administer radioactive medicinal products to women of childbearing potential,
information should always be sought about pregnancy. Any woman who has missed a period should
be assumed to be pregnant until proven otherwise. Where uncertainty exists it is important that
radiation exposure should be the minimum consistent with achieving the desired clinical information.
Alternative techniques which do not involve ionising radiation should be considered.
Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus.
Only imperative investigations should be carried out during pregnancy, when likely benefit exceeds the
risks incurred by mother and foetus.
Breast-feeding
Before administering a radioactive medicinal product to a mother who is breast-feeding consideration
should be given as to whether the investigation could be reasonably delayed until the mother has
ceased breast-feeding and as to whether the most appropriate choice of radiopharmaceutical has
been made, bearing in mind the secretion of activity in breast milk. If the administration is considered
necessary, breast-feeding should be interrupted for three days and the expressed feeds discarded.
Breast-feeding can be restarted when the level in the milk will not result in a radiation dose to a child
greater than 1 mSv.
4.7. Effects on the ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
4.8. Undesirable effects
The frequencies of the undesirable effects are defined as follows:
Very Common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000
to <1/1,000), Very Rare (<1/10,000) and not known (cannot be determined with the data available).

Cardiac disorders
Frequency not known (cannot be estimated
from the available data)
Congenital, familial and genetic disorders
Frequency not known (cannot be estimated
from the available data)
Respiratory, thoracic and mediastinal
disorders
Frequency not known (cannot be estimated
from the available data)
Gastrointestinal disorders
Frequency not known (cannot be estimated
from the available data)
Neoplasms benign, malignant and
unspecified (including cysts and polyps)
Frequency not known (cannot be estimated
from the available data
Vascular disorders
Frequency not known (cannot be estimated
from the available data
General disorders and administration site
conditions
Frequency not known (cannot be estimated
from the available data)
Immune system disorders
Frequency not known (cannot be estimated
from the available data)

Palpitations.
Hereditary defects.

Dyspnoea.
Abdominal cramps.

Cancer induction.
Transient hypertension.

Heat sensations.
Blushes, urticaria, nausea, cold chills and
other symptoms of anaphylactoid
reactions, hypersensitivity.

When the drug is administered too fast palpitations, dyspnoea, heat sensations, transient
hypertension and abdominal cramps may occur during or immediately after administration. Within
one hour these symptoms disappear.
For each patient, exposure to ionizing radiation must be justifiable on the basis of likely benefit. The
activity administered must be such that the resulting radiation dose is as low as reasonable
achievable bearing in mind the need to obtain the intended diagnostic or therapeutic result.
Exposure to ionising radiation is linked with cancer induction and a potential for development of
hereditary defects. For diagnostic nuclear medicine investigations the current evidence suggests that
these adverse effects will occur with low frequency because of the low radiation doses incurred.
For most diagnostic investigations using a nuclear medicine procedure the effective dose is less than
20 mSv. Higher doses may be justified in some clinical circumstances.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard.
4.9. Overdose
The effect of an overdose of iobenguane is due to the release of adrenaline. This effect is of short
duration and requires supportive measures aimed at lowering the blood pressure: Prompt injection of
a rapidly acting alpha-adrenergic blocking agent (phentolamine) followed by a beta-blocker
(propanolol). Because of the renal elimination pathway, maintaining the highest possible urine flow is
essential to reduce the influence of radiation. The nature of the radioisotope and the amount of
iobenguane present make overdosing improbable.
5.

PHARMACOLOGICAL PROPERTIES
Iobenguane is a radioiodinated aralkylguanidine. Its structure contains the guanidine-group from
guanethidine linked to a benzyl-group into which iodine is introduced. Like guanethidine the
aralkylguanidines are adrenergic neuron blocking agents. As a consequence of a functional similarity
between adrenergic neurons and the chromaffin cells of the adrenal medulla iobenguane is able to
localise preferentially in the medulla of the adrenal glands. In addition localisation in the myocardium
occurs.

5.1. Pharmacodynamic properties
Pharmacotherapeutic group: Diagnostic radiopharmaceuticals, tumour detection, iobenguane (123I),
ATC code: V09IX01
Of the various aralkylguanidines iobenguane is the preferred substance because of its lowest liver
uptake and its best in vivo stability, resulting in the lowest achievable thyroid uptake of liberated
iodide.
Transport of iobenguane across the cell membranes of cells originating from the neural crest is an
active process when the concentration of the drug is low (as in diagnostic dosages). The uptake
mechanism can be inhibited by uptake inhibitors such as cocaine or desmethylimipramine. After
uptake an active mechanism transfers at least part of the intracellular iobenguane into the storage
granules within the cells.

5.2. Pharmacokinetic properties
Iobenguane is to a large extent excreted unaltered by the kidneys. Of the administered doses 70 to
90% are recovered in urine within 4 days. The following metabolic breakdown products were
recovered in urine: radioiodide, radioiodinated meta-iodohippuric acid, radioiodinated hydroxyiodobenzylguanidine and radioiodinated meta-iodobenzoic acid. These substances account for
approximately 5 to 15% of the administered dose.
The distribution pattern of iobenguane includes rapid initial uptake in liver (33% of the administered
dose) and much less in lungs (3%), myocardium (0.8%), spleen (0.6%), and salivary glands (0.4%).
Uptake in normal adrenals (adrenal medulla) can lead to visualisation with [123I]iobenguane.
Hyperplastic adrenals show a high uptake.
5.3. Preclinical safety data
In dogs 20 mg/kg is a lethal dose. Lower dose levels (14 mg/kg) cause transient clinical signs of toxic
effect. Repeated intravenous administrations in rats of 20 to 40 mg/kg induce signs of serious clinical
toxicity. Repeated intravenous administrations of 5 to 20 mg/kg do induce effects, including
respiratory distress, but long term effects are only a slight increase in weight of liver and heart.
Repeated administration in dogs of 2.5 to 10 mg/kg do induce clinical effects, including increased
blood pressure and abnormalities in heart rate and in cardiac pulse propagation, but all signs were of
a transient nature.
In the test systems used no mutagenic effect could be demonstrated.
Studies of carcinogenic effects of iobenguane have not been published.
6.

PHARMACEUTICAL PARTICULARS

6.1. List of excipients
Benzyl alcohol
3-iodobenzylguanidine
Sodium dihydrogen phosphate dihydrate
Disodium hydrogen phosphate dihydrate
Water for injections.
6.2. Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
products.
6.3. Shelf life
Can be used up to 36 hours post calibration time indicated on the label.
Once opened, store in a refrigerator (2°C-8°C) and use within one working day.
6.4. Special precautions for storage
Store below 25°C. Do not freeze.
For storage conditions of the opened medicinal product, see section 6.3.
Store either in original lead container or in equivalent shielding.
Storage should take place in accordance with national regulations for radioactive materials.
6.5. Nature and contents of container
10 ml medicinal glass vial, closed with a Teflon coated rubber stopper and sealed with an
aluminium cap. Each vial is enclosed in a lead container of appropriate thickness.
Pack size: 37 to 740 MBq.
Not all pack sizes may be marketed.
6.6. Special precautions for disposal and other handling
Normal safety precautions for handling radioactive materials should be observed. After use,
all materials associated with the preparation and administration of radiopharmaceuticals,
including any unused product and its container, should be decontaminated or treated as
radioactive waste and disposed of in accordance with the conditions specified by the local
competent authority. Contaminated material must be disposed of as radioactive waste via an
authorised route.
7.

MARKETING AUTHORISATION HOLDER
GE Healthcare Limited
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
United Kingdom

8.

MARKETING AUTHORISATION NUMBER
UK: PL 00221/0140

9.

DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
UK

Date of first authorisation
01 December 1998

Date of last renewal
18 June 2002

10. DATE OF REVISION OF THE TEXT
09/2015

11. DOSIMETRY
The table below shows the dosimetry as calculated according to Publication 80 of the ICRP
(International Commission on Radiological Protection, Radiation Dose to Patients from
Radiopharmaceuticals, Pergamon Press 1998).
Organ

Absorbed dose per unit activity administered (mGy/MBq)
Adult
1.7E-02
4.8E-02
1.1E-02
4.7E-03
5.3E-03
2.1E-02

15 years
2.2E-02
6.1E-02
1.4E-02
6.0E-03
6.8E-03
2.5E-02

10 years
3.2E-02
7.8E-02
2.2E-02
9.9E-03
1.1E-02
3.6E-02

5 years
4.5E-02
8.4E-02
3.4E-02
1.6E-02
1.7E-02
5.4E-02

1 year
7.1E-02
1.5E-01
6.8E-02
2.9E-02
3.2E-02
1.0E-01

8.4E-03
8.4E-03
8.6E-03
9.1E-03
7.9E-03

1.1E-02
1.1E-02
1.1E-02
1.2E-02
1.0E-02

1.9E-02
1.8E-02
1.8E-02
2.0E-02
1.6E-02

3.0E-02
2.8E-02
2.9E-02
3.3E-02
2.3E-02

5.6E-02
5.1E-02
5.2E-02
5.8E-02)
4.3E-02)

Heart
Kidneys
Liver
Lungs
Muscles

1.8E-02
1.4E-02
6.7E-02
1.6E-02
6.6E-03

2.4E-02
1.7E-02
8.7E-02
2.3E-02
8.4E-03

3.6E-02
2.5E-02
1.3E-01
3.3E-02
1.3E-02

5.5E-02
3.6E-02
1.8E-01
4.9E-02
2.0E-02

9.7E-02
6.1E-02
3.3E-01
9.2E-02
3.7E-02

Oesophagus
Ovaries
Pancreas
Red marrow
Skin

6.8E-03
8.2E-03
1.3E-02
6.4E-03
4.2E-03

8.8E-03
1.1E-02
1.7E-02
7.9E-03
5.1E-03

1.3E-02
1.6E-02
2.6E-02
1.2E-02
8.2E-03

2.1E-02
2.5E-02
4.2E-02
1.8E-02
1.3E-02

3.7E-02
4.6E-02
7.4E-02
3.2E-02
2.5E-02

Spleen
Testes
Thymus
Thyroid
Uterus

2.0E-02
5.7E-03
6.8E-03
5.6E-03
1.0E-02

2.8E-02
7.5E-03
8.8E-03
7.3E-03
1.3E-02

4.3E-02
1.2E-02
1.3E-02
1.2E-02
2.0E-02

6.6E-02
1.8E-02
2.1E-02
1.9E-02
2.9E-02

1.2E-01
3.3E-02
3.7E-02
3.6E-02
5.3E-02

Remaining
organs

6.7E-03

8.5E-03

1.3E-02

2.0E-02

3.7E-02

Effective dose
(mSv/MBq)

1.3E-02

1.7E-02

2.6E-02

3.7E-02

6.8E-02

Adrenals
Bladder
Bone surfaces
Brain
Breast
Gall bladder
GI-tract
Stomach
SI
Colon
(ULI
(LLI

The effective dose resulting from an administered activity amount of 200 MBq is 2.6 mSv in
the adult.
The above data are valid in normal pharmacokinetic behaviour. When renal function is
impaired due to disease or due to previous therapy, the effective dose delivered to organs
might be increased.
12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
This radiopharmaceutical may be received, used and administered only by authorised persons in
designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the
regulations and/or appropriate licences of the local competent official organisations (see section 6.6).
The administration of radiopharmaceuticals creates risks for other persons from external radiation or
contamination from spills of urine, vomiting, etc. Radiation protection precautions in accordance with
national regulations must therefore be taken.
Solution for intravenous injection, ready to use. Aseptic conditions must be observed during
withdrawal of a patient dose from the vial, including microbial decontamination of the rubber stopper
with a suitable disinfectant before removal of a dose. This product is not preserved. After removal of a
dose from the vial, store at 2°C-8°C and use within one working day.
13. OTHER INFORMATION
Manufacturer
GE Healthcare B.V.
Den Dolech 2
5612 AZ Eindhoven
The Netherlands

AdreView is a trademark of GE Healthcare.

GE and the GE Monogram are trademarks of General Electric Company

GE Healthcare B.V.
P.O. Box 746
NL-5600 AS Eindhoven
T +31(0)40 299 1000
F +31(0)40 299 1299

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide